Efficacy of Su Jok Seed Therapy in Migraine: A Randomized Placebo-Controlled Study.

INTRODUCTION

Migraine is an important health problem that negatively affects individuals' activities of daily living. The decrease in the quality of life because of migraine increases the need for the development of new pharmacological and nonpharmacological treatment methods for pain management. Limited studies have reported the application of a traditional therapy, such as Su Jok seed therapy, to prevent or minimize migraine. This study aimed to examine the effect of Su Jok seed therapy on the severity, duration, and frequency of headaches in patients with migraine.

METHODS

The study was conducted between September 2020 and February 2021 with 47 students diagnosed with migraine. Of these, 24 patients were included in the intervention group and 23 in the placebo control group. Data were collected using a patient information form developed by the researchers, a migraine diary, the Numeric Pain Rating Scale (NPRS), and the Headache Impact Test-6 (HIT-6) questionnaire. Each patient in the intervention and placebo groups received eight sessions of Su Jok seed therapy, twice a week for 4 weeks. Data were evaluated at the 30th, 60th, and 120th min of the therapy using NPRS, before the therapy (pretest), after the therapy (posttest), and 4 weeks after the therapy (follow-up) using a migraine diary and the HIT-6 questionnaire.

RESULTS

Descriptive statistics (mean, standard deviation/standard error, and percentages) were used for data analysis. Student's t, Mann-Whitney U, repeated-measures analysis of variance, Bonferroni, Friedman, Dunn-Bonferroni, and χ2 tests were used in this study. Significance was set at p < 0.05. After the administration of Su Jok seed therapy, the difference in mean NPRS scores between the groups was significant (p < 0.05) from the 60th min of the administration. Furthermore, a significant decrease was observed in the severity, duration, and frequency of headaches; the HIT-6 questionnaire scores; and the amount of painkillers consumed by the patients in the intervention group after the therapy and in the follow-up period compared with the pretest data. Additionally, the level of satisfaction of the patients in the intervention group was significantly higher after the therapy than that of those in the placebo group.

CONCLUSION

Su Jok seed therapy reduced the severity, duration, and frequency of migraines, which in turn reduced the amount of painkillers consumed and the HIT-6 scores of patients with migraines.